Cell Medica to open cell therapy production facility

Published: 7-Nov-2013
Manufacturing Pharmaceutical

The GMP facility will be at the Max-Delbrück-Center of Molecular Medicine, Berlin-Buch, Germany


Specialist T cell therapeutics company, Cell Medica is opening a European commercial manufacturing facility at the Max-Delbrück-Center of Molecular Medicine within the biotechnology park of Campus Berlin-Buch, Germany. The facility for the GMP production of cell and gene therapies includes approximately 350 m2 cleanroom space.

Initial manufacturing will focus on Cytovir CMV – an innovative treatment which uses the immune cells of a healthy donor to restore viral immunity against cytomegalovirus infections in patients who are immunocompromised following allogeneic hematopoietic stem cell (bone marrow) transplant. The commercial launch of this product is planned in early 2014.

The facility will also be important for Cell Medica’s planned CITADEL study for the investigation of Cell Medica’s T cell therapy for the treatment of EBV-associated lymphomas.

Cytovir CMV is available on clinician’s request in the UK only. In Germany, the competent authority has confirmed that Cytovir CMV can be placed on the market under a manufacturing license.

  • Companies:
  • Cell Medica
See more

You may also like

Design & Build

Cell and Gene Therapy Catapult opens manufacturing centre

Read more
More than £60 million of UK government investment is being used to develop the new centre, which aims to accelerate growth of the industry in the UK

Trending Articles

  1. Sartorius Stedim Biotech supports bioprocess development with new Innovation Centre The Massachusetts, US-based Centre for Bioprocess Innovation is a collaborative space designed to develop and optimise biomanufacturing processes
  2. IMed Consultancy helps Toby Orthopaedics navigate UK regulations Regulatory consultancy ensures compliance and confidence for Miami-based company
  3. Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
  4. IMed supports K2 medical systems in their EU MDR transition Consultancy firm helps K2 navigate the complex regulatory process to achieve Article 97 compliance

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

You may also like

Design & Build

Cell and Gene Therapy Catapult opens manufacturing centre

More than £60 million of UK government investment is being used to develop the new centre, which aims to accelerate growth of the industry in the UK
Pharmaceutical

Cell Medica begins commercial production at cell therapy facility in Germany

The first product has been manufactured and delivered to the patient
Manufacturing

Leybold launches Duradry vacuum pump for harsh processes

Advanced technology designed for reliability and efficiency
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Manufacturing

Anton Paar expands Litesizer DIA Series with new models

Introducing affordable and advanced solutions for particle analysis
Manufacturing

Triple your efficiency with the new DrySyn Vortex

Boost productivity with temperature-controlled parallel reactions
Manufacturing

Five critical design elements for Pelton wheel turbine flowmeters

Titan Enterprises outlines the factors for cost-effective and reliable low-flow measurement
Subscribe now